Kim KB - Search Results

1

Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease.

Lee MJ, Bhattarai D, Jang H, Baek A, Yeo IJ, Lee S, Miller Z, Lee S, Hong JT, Kim DE, Lee W, Kim KB. Lee MJ, et al. Among authors: kim de, kim kb. J Med Chem. 2021 Aug 12;64(15):10934-10950. doi: 10.1021/acs.jmedchem.1c00291. Epub 2021 Jul 26. J Med Chem. 2021. PMID: 34309393 Free PMC article.

2

Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening.

Miller Z, Kim KS, Lee DM, Kasam V, Baek SE, Lee KH, Zhang YY, Ao L, Carmony K, Lee NR, Zhou S, Zhao Q, Jang Y, Jeong HY, Zhan CG, Lee W, Kim DE, Kim KB. Miller Z, et al. Among authors: kim de, kim kb, kim ks. J Med Chem. 2015 Feb 26;58(4):2036-41. doi: 10.1021/jm501344n. Epub 2015 Feb 17. J Med Chem. 2015. PMID: 25658656

3

Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.

Lee MJ, Bhattarai D, Yoo J, Miller Z, Park JE, Lee S, Lee W, Driscoll JJ, Kim KB. Lee MJ, et al. Among authors: kim kb. J Med Chem. 2019 May 9;62(9):4444-4455. doi: 10.1021/acs.jmedchem.8b01943. Epub 2019 Apr 19. J Med Chem. 2019. PMID: 30964987 Free PMC article.

4

LMP2 Inhibitors as a Potential Treatment for Alzheimer's Disease.

Bhattarai D, Lee MJ, Baek A, Yeo IJ, Miller Z, Baek YM, Lee S, Kim DE, Hong JT, Kim KB. Bhattarai D, et al. Among authors: kim de, kim kb. J Med Chem. 2020 Apr 9;63(7):3763-3783. doi: 10.1021/acs.jmedchem.0c00416. Epub 2020 Mar 30. J Med Chem. 2020. PMID: 32189500

5

A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer's disease.

Yeo IJ, Lee MJ, Baek A, Miller Z, Bhattarai D, Baek YM, Jeong HJ, Kim YK, Kim DE, Hong JT, Kim KB. Yeo IJ, et al. Among authors: kim de, kim yk, kim kb. Sci Rep. 2019 Dec 5;9(1):18393. doi: 10.1038/s41598-019-54846-z. Sci Rep. 2019. PMID: 31804556 Free PMC article.

6

Inhibitors of the immunoproteasome: current status and future directions.

Miller Z, Ao L, Kim KB, Lee W. Miller Z, et al. Among authors: kim kb. Curr Pharm Des. 2013;19(22):4140-51. doi: 10.2174/1381612811319220018. Curr Pharm Des. 2013. PMID: 23181576 Free PMC article. Review.

7

The immunoproteasome as a therapeutic target for hematological malignancies.

Miller Z, Lee W, Kim KB. Miller Z, et al. Among authors: kim kb. Curr Cancer Drug Targets. 2014;14(6):537-48. doi: 10.2174/1568009614666140723113139. Curr Cancer Drug Targets. 2014. PMID: 25059201 Review.

8

The immunoproteasome: an emerging therapeutic target.

Lee W, Kim KB. Lee W, et al. Among authors: kim kb. Curr Top Med Chem. 2011 Dec;11(23):2923-30. doi: 10.2174/156802611798281348. Curr Top Med Chem. 2011. PMID: 21824107 Review.

9

High-Resolution Snapshots of Proteasome Inhibitors in Action Revise Inhibition Paradigms and Inspire Next-Generation Inhibitor Design.

Carmony K, Lee W, Kim KB. Carmony K, et al. Among authors: kim kb. Chembiochem. 2016 Nov 17;17(22):2115-2117. doi: 10.1002/cbic.201600488. Epub 2016 Oct 11. Chembiochem. 2016. PMID: 27605113 Free PMC article.

10

Tethered polymer nanoassemblies for sustained carfilzomib release and prolonged suppression of proteasome activity.

Reichel D, Lee MJ, Lee W, Kim KB, Bae Y. Reichel D, et al. Among authors: kim kb. Ther Deliv. 2016 Oct;7(10):665-681. doi: 10.4155/tde-2016-0041. Ther Deliv. 2016. PMID: 27790952

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,308 results

Search Page